Losing British drug giant AstraZeneca from the London Stock Exchange would be a “devastating blow”, Tory former chancellor ...

The Leader-Post Rider Rumblings podcast is back for Episode 168 as sports editor Taylor Shire and columnist Darrell Davis preview the Saskatchewan Roughriders upcoming game on Friday night against the ...

SAN FRANCISCO, CA, UNITED STATES, July 7, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Prothrombin Complex Concentrate Market during the forecasted period ...

Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical ...

CSL (ASX:CSL) global head of research and development Bill Mezzanotte likens drug development to falling in love.

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

The company was founded in 1986 and is headquartered in Dublin, Ireland. Shire plc operates as a subsidiary of Takeda Pharmaceutical Company Limited.

About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.

Takeda Pharmaceutical Company Limited / Key word (s): Personnel Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 30-Jan-2025 / 09:31 ...

In fiscal year 2023, the company reported revenue of 4.263 billion yen, or around 28 billion dollars, an increase of 5.7% from the previous year. Takeda has more than 5,700 employees in Massachusetts.

Norfolk-based biopharma company ReAlta Life Sciences has appointed David Marek its CEO and Paolo Martini its chief research and development officer, the company announced Thursday. “I am confident ...

Prior to Moderna, Martini was Senior Director of discovery biology and translational research at Shire Pharmaceutical. He played a key role in the launch of V-Priv (velaglucerase alpha) for Gaucher ...